|
Boston Scientific Bolsters AFib Mapping | Hypertension’s Digital Problem
November 7, 2024
|
|
|
|
|
Together with
|
|
|
|
“Patients expect that clinically-focused digital solutions are improving their health. We can talk about competing on user experience… but we need to prove that they work.”
|
|
Peterson Health Technology Institute’s response to pushback on its new report questioning the benefits of many digital hypertension management solutions.
|
|
|
|
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. for an undisclosed sum.
Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
Cortex might not be a household name outside of electrophysiology circles, debuting less than a year ago with $90M in funding, but it was actually formed from longtime EP mapping innovator Ablacon.
- In fact, Ablacon’s Electrographic Flow (EGF) mapping technology appears to be the foundation of Cortex’s FDA-cleared OptiMap system, which combines a basket-shaped catheter and custom algorithm to detect AFib sources and support personalized ablation strategies.
The acquisition continues Boston Scientific’s 2024 M&A spree, following its purchase of Silk Road Medical to expand its stroke portfolio ($1.26B), and Axonics to add to its urology capabilities ($3.7B).
- Although Cortex was surely a smaller investment, it’s similarly intended to boost a core BSCI focus area – electrophysiology mapping and ablation – especially noting the huge mapping advantages held by some of its competitors.
- Boston Scientific didn’t mention pulsed field ablation in its announcement, but it’s likely that the company also had PFA in mind, given the technology’s rapid growth and Cortex’s complex AFib mapping specialization.
Early signs suggest that OptiMap could bring big improvements, noting that the FLOW-AF trial demonstrated that OptiMap-guided treatment improved persistent AFib patients’ freedom from AFib by 51% after one year compared to patients who received conventional pulmonary vein isolation.
- Cortex also has more research on the way that could show OptiMap’s efficacy among a far wider range of AFib patients.
The Takeaway
Boston Scientific’s electrophysiology business was already on solid ground, growing by an impressive 177% last quarter, and this acquisition could help keep that momentum going by adding to the part of its EP portfolio that arguably has the most room for growth.
|
|
|
Automate Your Echo Reporting
It’s a good feeling when your echo report is already 83% complete before you even sit down to work on it. See how Centricity Cardio Enterprise’s echo automation features make this “good feeling” an everyday occurrence in this quick GE HealthCare demo video.
|
|
Forging the Future of Cardiovascular Care
Cardiology is changing, and for the better. Get a view into Lee Health Heart Institute’s medical director Richard Chazal, MD’s vision for a new era in cardiology, driven by imaging, AI and personalized medicine.
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
- PHTI Digital Hypertension Problem: Peterson Health Technology Institute’s latest report found that digital hypertension solutions vary significantly in performance, and many aren’t effective enough to justify their price. The PHTI report assessed clinical and economic evidence across BP monitoring, medication management, and behavior change, finding that only the first category demonstrated significant enough risk reductions to justify its added costs. Check out Digital Health Wire for the full story.
- CVRx’s Outpatient Payment: CMS gave physicians one more reason to consider CVRx’s Barostim neuromodulation system to treat heart failure, assigning it New Technology Ambulatory Payment Classification (APC) 1580. The $45,000 ambulatory payment joins a $43k reimbursement for inpatient use that was recently increased from a max of $23k.
- Vivasure’s PerQseal Shows Promise: Impressive results from Vivasure’s IDE PATCH study presented at TCT showed a 0.8% major complication rate among patients treated with its PerQseal Closure Device. The study examined the PerQseal Device’s safety and efficacy in achieving femoral arteriotomy hemostasis in patients undergoing PCI, finding a time-to-hemostasis of zero minutes. Due to the PerQseal’s sutureless and fully absorbable design, it’s the first minimally invasive venous closure method.
- Remote Cardiac Arrest Revival: Demonstrating the potential of remote care, Mayo Clinic successfully revived a patient suffering cardiac arrest while she was four miles away from the hospital. During a 10-minute telemedicine encounter, Mayo Clinic used OPTAC-X’s wearable assisted reality video system to connect paramedics with on-call EM physicians via Zoom. Thanks to the OPTAC-X’s strong signal, the EMS crew was able to receive guidance from physicians even in the patient’s basement.
- ACURATE IDE Dispoints: In what could be a setback for its FDA and commercial ambitions, Boston Scientific’s ACURATE neo2 aortic valve missed its primary endpoint in the ACURATE IDE trial. The study compared the ACURATE neo2 against two leading valves in patients with severe AS (Edwards SAPIEN and Medtronic Evolut), finding that that ACURATE neo2 patients had a higher composite rate of mortality, stroke, and rehospitalization at one year compared to control group patients (16.16% vs. 9.53%).
- Tempus and Northwestern’s ECG AI Alliance: Northwestern Medicine deployed Tempus’ ECG-AF algorithm to identify patients at increased risk of developing atrial fibrillation and seven structural heart diseases, including valvular diseases, abnormal heart function, and heart thickening. The collaboration makes Northwestern the first provider to clinically deploy the 12-lead ECG-based algorithm.
- To Sit or Stand for HTN? Though standing desks continue to rise in popularity, new research suggests that they may not reduce hypertension risks and could even make things worse. An AHA study found that standing for a few extra hours per day was not associated with any sort of reduction in blood pressure. In fact, some participants who experimented with a standing desk showed increases in central arterial stiffness.
- CT AI’s Predictive Promise: Late-breaking TCT study results showed that cardiac CT analysis using Cleerly’s AI-based ISCHEMIA solution can predict serious cardiac events in patients with coronary artery disease symptoms. Among over 3.5k patients, the two strongest predictors of MACE were diameter stenosis percentage and noncalcified plaque volume (HRs: 1.251 & 1.069), the latter of which was linked to adverse patient outcomes. These two factors were more predictive than traditional clinical risk scores, suggesting AI-driven evaluations could help guide treatment decisions.
- Dual Drug DCB: Advanced NanoTherapies announced positive results from the first-in-human trial evaluating its SirPlux Duo Drug-Coated Balloon, which uses a dual-drug therapy of sirolimus and paclitaxel for vessel patency and restenosis prevention. By combining the two drugs, the SirPlux aims to minimize drug flaking and deliver sustained therapeutic dosing, theoretically making it a front-line alternative to current DCBs or drug-eluting stents. The company now plans to begin the DYNAMIC DUO I early feasibility study to evaluate the SirPlux in de novo coronary lesions.
- Acarix APC Expansion: Acarix’s CADScor cardiac acoustic waveform test for coronary artery disease received CMS’ APC 5733 designation as well as an “S” status indicator (separately payable) for 2025. This means CADScor can receive standalone fixed reimbursement in outpatient settings, while the certainty of payment that comes with its “S” code designation could accelerate usage in ER and ambulatory settings. CADScor already received the 8th most CPT reimbursement claims among all AI products from 2018 to 2023.
- GLP-1 Surgical Guidelines: The American Society of Anesthesiologists (ASA) sharply contrasted its 2023 GLP-1 surgical guidance with a new statement that patients should not stop taking GLP-1s prior to elective surgery. The ASA originally advised a 1-week and 1-day hold of injectable and oral GLP-1 agents because they delay gastric emptying and could increase regurgitation risk under anesthesia. Now patients can continue their medication but should follow a liquid diet for 24 hours before the procedure.
|
|
Addressing Coronary Artery Disease
Learn how the AGENT™ Drug-Coated Balloon provides a new treatment option for in-stent restenosis in the U.S. Rx Only. (Sponsored by Boston Scientific)
|
|
A Better Way to Coordinate Post-Stroke Care
Think your EHR messaging system might be holding back your post-stroke care? See how UC San Diego Medical Center streamlined its neuro and EP teams’ post-stroke workflow with Viz Connect, and the impact it had on cardiac monitor placements in inpatient and outpatient settings.
|
|
New Horizons in Structural Heart
TAVR and TMVR rates are rising rapidly, placing more pressure on interventional planning. Tune into this Circle CVI and Radcliffe Cardiology breakout detailing how to leverage modern CT workflows to produce efficient and accurate pre-procedural plans.
|
|
- How to Improve Cardiology Workflows and Get More Patient Time: Complex processes and reporting requirements can mean cardiologists spend more time with clinical systems than they do with their patients. See how Merge Hemo and Merge Cardio work together to help you streamline and scale your clinical and data management workflows, so you can have more time in front of your patients.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
- How to Plan Your Cloud Migration: Ready to move your enterprise imaging to the cloud? Explore the different pathways to the cloud, and the advantages available through a cloud-native platform in this Optum white paper.
- Relieving The Burden of Post-Processing: With the advent of advanced imaging technologies like CCTA come added burdens to technologists and diagnostic imaging centers. See how PIA can relieve the burden of post-processing, saving you time while helping your bottom line.
- HeartFlow FFRCT Catches Missed Blockages: Karen Moore had always been diligent about her heart health, which is why she was concerned when she began showing symptoms of heart disease but all of her tests came back negative. See how Karen and her physician used HeartFlow FFRCT to catch a 90% blockage and place a stent in the right location, before it was too late.
- Harnessing the Power of AI to Improve Patient Care: Endeavor Health is one of the first healthcare providers in the Midwest to use AI in the echocardiography lab. Learn how they are harnessing echo AI’s tremendous potential to improve diagnoses in this report from Us2.ai.
- Advance Your Cardiac MR Visualization: Ready to advance your CMRI assessments? See how you could leverage TeraRecon’s Intuition Cardiac MR package for a range of cardiac anatomy and physiology evaluations, and how your peers are already benefiting from it.
- Accurately Measuring Heart Rate Variability: Heart rate variability measurement and analysis involves two critical elements – the ability to accurately discern the R wave in noisy environments, and using the correct analysis method for a given application. Check out how Monebo’s Kinetic HRV ECG Algorithm excels at both of these essential tasks.
|
|
|
|
|
